Pharma lobbying spend on FDA-related issues rises 20% in 2026

In response to calls for regulatory stability, pharmaceutical companies will increase lobbying expenditures focused on FDA-related issues by at least 20% in 2026 compared to 2025, as reported by transparency groups.

Implied probability (Yes)

75%